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Abstract
The vascular endothelial growth factor VEGF-D promotes
metastasis by inducing lymphangiogenesis and dilatation of
the lymphatic vasculature, facilitating tumor cell extravasion.
Here we report a novel level of control for VEGF-D expression
at the level of protein translation. In human tumor cells,
VEGF-D colocalized with eIF4GI and 4E-BP1, which can
program increased initiation at IRES motifs on mRNA by the
translational initiation complex. In murine tumors, the
steady-state level of VEGF-D protein was increased despite
the overexpression and dephosphorylation of 4E-BP1, which
downregulates protein synthesis, suggesting the presence of an
internal ribosome entry site (IRES) in the 50 UTR of VEGF-D
mRNA. We found that nucleolin, a nucleolar protein involved
in ribosomal maturation, bound directly to the 50UTR of
VEGF-D mRNA, thereby improving its translation following
heat shock stress via IRES activation. Nucleolin blockade by
RNAi-mediated silencing or pharmacologic inhibition reduced
VEGF-D translation along with a subsequent constriction of
lymphatic vessels in tumors. Our results identify nucleolin as
a key regulator of VEGF-D expression, deepening understand-
ing of lymphangiogenesis control during tumor formation.
Cancer Res; 76(15); 4394–405. 2016 AACR.
Introduction
Lymphatic vessels encircle tumors and enhance metastasis by
improving the capillary high permeability and the collecting
vessels' dilatation (1). Nonetheless, very little is known regarding
the molecular mechanisms governing cancer invasion into the
lymphatic system.
VEGF-C and VEGF-D are the chief inducers of lymphangio-
genesis (2). Their activity is regulated by protein processing that
occurs mainly in the extracellular environment to generate
peptides with high afﬁnity for their receptor, VEGFR-3 (3, 4).
Our group recently identiﬁed regulation of VEGF-C at the
translational initiation step induced by hypoxic stress (5). The
stress-induced VEGF production in pathologic conditions has
been largely described in the literature (6, 7). In this study, we
sought to identify whether VEGF-D activity responds to cellular
stress.
VEGF-D was ﬁrst described to promote tumor metastasis
through the lymphatic system (8, 9). This observationwas extend-
ed to many solid tumors such as pancreatic cancer and endome-
trial cancer (10, 11). More recently, Karnezis and colleagues have
demonstrated that the prometastatic effect of VEGF-D was asso-
ciated with a lymphatic collecting vessel dilatation by regulating
the prostaglandin pathway (1). The effect of VEGF-D on vessel
enlargement was also observed in dermal initial lymphatics (12).
Here, we found an original mechanism underlying regulation of
VEGF-D translation that is induced by increased temperature.
Translational control plays a critical role in the regulation of
gene expression during tumor development (13). In fact, the
majority of cellular stresses lead to strong inhibition of mRNA
translation by the classical cap-dependent scanning mechanism
(5, 14). Several mRNAs, however, are translated by an eIF4E-
independent mechanism, mediated by internal ribosome entry
site (IRES) that are mRNA structures located in IRESs were
previously described for VEGF-A and VEGF-C mRNA (15, 16).
Here, we demonstrated that the 50UTR of VEGF-DmRNA harbors
an IRES trans-acting factor, which drives VEGF-D translation
under heat shock stress.
IRES-dependent translation initiation is controlled by IRES
trans-acting factors (ITAF), which participate in the recruitment
of the small ribosome subunit (17). ITAFs seemingly stabilize the
IRES active conformation (18) to allow efﬁcient expression of key
regulators in tumor growth and spreading (16). The activity of
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ITAFs is dependent on their subcellular localization. They are
nuclear proteins that are exported to the cytoplasm to participate
in mRNA translation initiation (19). ITAFs bind the mRNA 50
untranslated region to recruit the ribosome, thereby promoting
protein synthesis under stress conditions. Here, we found that
nucleolin, a multifunctional nucleolar protein involved in ribo-
some maturation, is an ITAF of the VEGF-D mRNA. Speciﬁcally,
our data showed that cytoplasmic accumulation of nucleolin in
cells enduring heat shock improvedVEGF-DmRNA translationby
binding of ITAF to the VEGF-D 50 UTR.
Nucleolin was ﬁrst described to be an ITAF for viral 50UTR
mRNAs such as rhinovirus (20). Recently, nucleolin was shown to
participate in IRES-dependent translation of cellular mRNAs. It
associated with hnRNP proteins to promote translation of long
interspersed element one (LINE-1; ref. 21). Moreover, recent
reports conﬁrmed the ITAF activity of nucleolin during tumori-
genesis and demonstrated that it is a key regulator of speciﬁcity
protein 1 (Sp1) protein accumulation via induction of its IRES-
dependent translation initiation (22).
In the current study, we demonstrate a link between the
translational control of VEGF-D expression and lymphatic dila-
tation. We show that RNA-binding protein nucleolin speciﬁcally
and directly binds to the 50UTR of VEGF-D and functions to
induce VEGF-D mRNA translation in cells. Our results advocate
that nucleolin contributes to themaintenance of lymphatic vessel
plasticity under heat shock stress conditions by controlling VEGF-
D expression.
Of interest, inhibition of nucleolin synthesis by NSAIDs spe-
ciﬁcally repressed VEGF-D translation, suggesting a putative pro-
tein synthesis control using NSAIDs that could interfere with a
physiologic function such as lymphatic dilatation.
Altogether, our results suggest that nucleolin contributes to the




In total, 15 primary human breast cancer specimens and their
associated lymph nodes were collected. Samples were obtained
from archival parafﬁn blocks of breast cancer from patients
treated at the Rangueil hospital (Toulouse, France) between
2002 and 2008. Samples were selected as coded specimens
under a protocol approved by the INSERM Institutional Review
Board (DC-2008-463) and Research State Department (Minis-
tere de la recherche, ARS, CPP2, authorization AC-2008-820)
and included tumor specimens identiﬁed as invasive ductal
carcinoma. Each series included as controls normal breast
tissue from the same patient.
Tumor studies
Animal experimentswere conducted in accordancewith recom-
mendations of the European Convention for the Protection of
Vertebrate Animals used for experimentation. All animal experi-
ments were performed according to the INSERM Institutional
Animal Care and Use Committee guidelines for laboratory ani-
mals' husbandry and have been approved by the local branch
INSERM Rangueil-Purpan of the Midi-Pyrenees ethics committee
(protocol n 091037615).
In total, 5 105 cells of murine Lewis Lung Carcinoma (LLC1;
ATCC CRL-1642; obtained in 2011) and human pancreatic ade-
nocarcinoma (Capan-1, ATCC HTB79; obtained in 2009) cell
lines were injected subcutaneously into wild type (WT, n¼ 8–10)
mice on a C57Bl6 or NMRI Nu/Nu background, respectively (n¼
8–10).Animalswere sacriﬁced2or3weeks laterwhen tumors and
inguinal lymph nodes were excised and embedded into optimal
cutting temperature (OCT) compound (Tissue-Tek; Sakura Fine-
tek). To study the orthotopic model of breast carcinoma, 5 104
syngeneic Balb/c 4T1 and 67NR (ATCC CRL-2539, obtained in
2007) cells were injected into Balb/c the fourth mammary fat pad
(n¼ 8–10). Animalswere sacriﬁced 1or 2weeks laterwhen tumor
and inguinal lymph nodes were excised and embedded into OCT
compound.
Bicistronic lentivector construction and transduction
The cDNAs coding human VEGF-D 50UTR and EMCV 50UTR
were subcloned between the Renilla (LucR) and ﬁreﬂy (LucF)
genes under the control of the CMV promoter into the lentivector
pTRIP-DU3-CMV-MCS as described previously (5). Bicistronic
lentivectors were produced using the tri-transfection procedure
using the plasmids pLvPack and pLvVSVg (Sigma-Aldrich), and
were evaluated for their ability to transduce the cell lines as
described previously (5).
Reporter gene assay
To obtain stable vector expression in cells, the bicistronic
cassette with the VEGFD 50UTRs between the two luciferase genes
was introduced into lentivectors. Bicistronic lentivectors with the
viral EMCV IRES and the hairpin were used as negative and
positive controls. The principle of the bicistronic vector is that
the ﬁrst cistron, Renilla luciferase (LucR), is translated by the cap-
dependent mechanism, whereas the second cistron, ﬁreﬂy lucif-
erase (LucF), is translated under the control of the IRES. In vitro or
ex vivo luciferase assays were performed on lysed cells or tissues as
described previously (5).
Reagents
Rat anti-mouse VEGFD (SC101585) was from Santa Cruz
Biotechnology (TebuBio). Rabbit-anti human 4E-BP1 (9644)was
fromOzyme. Rabbit anti-mouse -1 antibody (RDI-103PA50) was
from Research Diagnostics Incorporated. Rat anti-mouse CD31
(MEC 13.3) was fromBDBiosciences. Goat anti-PAN cytokeratin,
donkey anti-rabbit, and rat IgGs conjugated with Dylights Fluors
488, 568 were from TebuBio. Anti-podoplanin was from Santa
Cruz Biotechnology. Anti-luciferase Fireﬂy was from Promega.
Hypoxyprobe was from Euromedex. Anti-GAPDH was from Sig-
ma Aldrich.
Immunohistochemistry
Tumors and lymph nodes were embedded into OCT com-
pound and 5-mm tissue sections were immunostained with spe-
ciﬁc antibodies. The mean number of lymphatic vessels (SEM
for each treatment group) were quantiﬁed in 5–10 microscopic
ﬁelds per cryosection using automated pixel density determina-
tion. The vessel diameters were quantiﬁed using 5 measures per
vessel as described in Supplementary Fig. S1. In total, 3 sections/
tumor were analyzed (8–10 tumors per group), 5 microscopic
ﬁelds/section leading to 100–150 ﬁelds/condition. The mean
number of mice with lymph node metastases was determined
by immunostaining with 10 mg/mL of anti-pancytokeratin and
quantiﬁed in 5–10 microscopic ﬁelds per cryosection using
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automated pixel density determination as the mean number of
pixels  SEM for each group.
Quantitative real-time RT-PCR
Total cellular RNAwas isolated frommouse 4T1, 67NR,Capan-
1, and LLC tumors using a tissue lyser (Ultrathurax) in TRIzol
solution as described previously (5).
Primers. The following primers were used: LucF forward (F): 50-
TCCTATGATTATGTCCGGTTATGTAAA-30; LucF reverse (R): 50-
TGTAGCCATCCATCCTTGTCAA-30; LucR (F): 50- ATGGGCAAAT-
CAGGCAAA-30; LucR (R): 50- CGCAATATCTTCTTCAATATCAGG-
30; VEGF-D (F): 50- CCTATTGACATGCTGTGGGAT-30; VEGF-D
(R): 50-GTGGGTTCCTGGAGGTAAGAG-30
siRNA and cell transfection
A pool of siRNAs synthesized by Dharmacon with the follow-
ing sequences: siRNA-1: 50-GCAAAUUCCUAUACAUCUA-30,
siRNA-2: 50-UGUCAGAGGUCCAGUUUAA-30, siRNA-3: 50-UGG-
CAAACCUAAAGGGUAU-30, siRNA-4: 50-UGGGAAAAGUAAA-
GGGAUU-30 were used. Nontargeting siRNA (siGENOME Non-
Targeting Smartpool; Dharmacon) was used as control. To exam-
ine the effect of the siRNAs on nucleolin protein expression, 4T1
cells were plated onto 6-well plates in antibiotic-free RPMI1640
medium supplemented with FBS (10%) before being transfected
with 20nmol/L siRNAasdescribed previously (5). Vehicle control
and nontargeting siRNA were applied to cell culture replicates.
Cells were incubated for 1 day before changing the culture
medium and incubating them for 72 hours before the 30-minute
heat shock. Efﬁcacy of downregulation was analyzed by
immunoblotting.
N6L inhibitor treatment
N6L, a synthetic ligand of nucleolin that exerts antitumor
activity in mouse xenograft model (23), was provided by J.
Courty's laboratory (Laboratoire CRRET Laboratory, Universite
Paris EST Creteil, Creteil, France). Stock solution of N6L
(2 mmol/L) was diluted in mannitol to a ﬁnal concentration
of 50 mmol/L. Heat shock was applied for 30 minutes at 42C.
In vitro stress-induced IRES activity
Stress stimulation assays were performed in vitro on 4T1-trans-
duced cells. Reticulum stress was promoted using 12 nmol/L
dithiothreitol (DTT; Sigma-Aldrich) during 4 and 8 hours. Dep-
rivation stress was performed in RPMI without serum during 8
hours at 37C. Inﬂammatory stress was performed in the presence
of 1 mg/mL lipopolysaccharid (LPS; Sigma-Aldrich Chemie
GmbH) during 4 and 8 hours. Heat shock was applied during
5, 10, 20, and 30 minutes at 37C.
In vivo sc-236 treatment
NSAID treatment was performed by injecting 1 mg of anti-COX-
2 inhibitor sc-236 (Sigma-Aldrich Chimie GmbH) every 2 days
during 12 days. Tumor-bearingmice were sacriﬁced after 2 weeks.
RNA structure determination in solution chemical and
enzymatic probing
RNA preparation, RNA structure probing, and RNA primer
extension analysis were performed as described previously (5).







Biomolecular analysis coupled to mass spectrometry (BIA-MS)
was performed on a BIAcore T200 optical biosensor instrument
(GE Healthcare). Immobilization of biotinylated VEGF-D and
EMCV IRES RNAs was performed on a streptavidin-coated (SA)
sensorchip in HBS-EP buffer (10 mmol/L HEPES, pH 7.4, 150
mmol/L NaCl, 3 mmol/L EDTA, 0.005% surfactant P20; GE
Healthcare). All immobilization steps were performed at a ﬂow
rate of 2mL/minutewith aﬁnal concentration of 100 mg/mL. Total
amount of immobilized VEGF-D and EMCV IRES RNAs was 552
RU and 650 RU, respectively.
Binding analyses were performed with cell protein extracts at
100 mg/mL over the immobilized VEGF-D and EMCV IRES RNA
surface at 37C and 42C for 7 minutes at a ﬂow rate of 30 mL/
minute. The channel (Fc1) was used as a reference surface for
nonspeciﬁc bindingmeasurements. The recovery wizard was used
to recover selected proteins from cell protein extracts at 37C and
42C. This step was carried out with 0.1% SDS. Five recovery
procedures were performed to get enough amounts of proteins for
MS identiﬁcation. LC/MS-MS analyses were performed on Bruker
Amazon ETD mass spectrometer.
Polysome proﬁling. 4T1 cell line were incubated with cyclohexi-
mide (100mg/mL)15minutes at 37Cbefore preparing extracts in
hypotonic lysis buffer (5 mmol/L Tris-HCl, pH7.5; 2.5 mmol/L
MgCl2; 1.5 mmol/L KCl). Cell extracts were layered onto 10%–
50%sucrose gradient and sedimented via centrifugation at 39,000
rpm for 2 hours at 4C in a Beckman ultracentrifuge. Fractions
were collected (24 fractions of 12 drops each) using a Foxy JR
ISCO collector and UV optical unit type 11.
Statistical analysis
All statistical analyses were performed using a two-tailed Stu-
dent t test or one-way ANOVA. All experiments were performed
three times, with one exception, where the incidence ofmetastasis
is reported as the average  SEM of three separate animal experi-
ments. All data presented are from a single representative
experiment.
Results
VEGF-D synthesis ismodulated by a cap-independent initiation
of mRNA translation
VEGF-D levelwas examined in invasive ductal breast carcinoma
biopsies and compared with normal breast epithelium (Fig. 1A).
VEGF-D is overexpressed in breast tumors and is associated with
an upregulation of eIF4GI and 4E-BP1 expressions, suggesting a
cap-independent VEGF-D synthesis.
To study the expression of VEGF-D, we performed RT-qPCR
and Western blot analysis showing that VEGF-D is ubiquitously
expressed in organs containing lymphatic vessels (lymph nodes,
mammary gland, etc.), whereas no VEGF-D was found in organs
containing no (brain) or low level (muscle) of lymphatic vessels
(Supplementary Fig. S2).
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To study the effect of the microenvironment on lymphatic
vessel development in vivo, we used mouse tumor models, which
we previously showed to early induce lymphangiogenesis: an
orthotopic syngeneic mouse model of highly metastatic breast
cancer (4T1); a syngeneic subcutaneous model of Lewis lung
carcinoma (LLC); and a xenograft model of pancreatic adenocar-
cinoma (Capan-1; Fig. 1B). We studied the expression of VEGF-D
and surprisingly found that VEGF-D mRNA levels strongly
decreased in tumors compared with normal tissues (Fig. 1B).
Despite the decrease in VEGF-DmRNA amounts, VEGF-D protein
level increased during breast tumor development, but not in lung
and pancreas (Fig. 1C and D), conﬁrming a posttranscriptional
regulation of VEGF-D expression.
In parallel, we analyzed regulation of translation initiation in
mice tumors by studying the phosphorylation status of 4E-BP1,
which is known to inhibit cap-dependent translation by binding
to eIF4E in its hypophosphorylated state (Fig. 1C–E).
As expected, VEGF-D protein synthesis was not stimulated in
lung and pancreatic tumors containing hypophosphorylated 4E-
BP1 comparedwith normal tissue (Fig. 1C–E). In contrast, despite
an accumulation of hypophosphorylated 4E-BP1 indicating a
blockade of cap-dependent translation in breast cancer compared
with normal breast, we observed an increase in VEGF-D expres-
sion in the tumors in vivo (Fig. 1C–E). These data suggest that
VEGF-D expression is promoted by a posttranscriptional mech-
anism in breast cancer.
VEGF-D mRNA 50UTR contains an IRES activated by increased
temperature
To demonstrate the presence of an IRES activity in VEGF-D
mRNA 50UTR, we used the double luciferase bicistronic vector
strategy validated in previous studies (Fig. 2A; ref. 5). Consid-
ering that the EMCV IRES is not activated in the current tumor
models (5), we used bicistronic lentivectors with the EMCV
IRES and hairpin as controls to transduce 4T1 and 67NR with
the bicistronic lentivectors (Fig. 2A). To verify the presence of a
single mRNA that generates the two different proteins, the
relative amounts of LucR and LucF mRNAs were measured by
quantitative RT-PCR (Fig. 2B). Ampliﬁcation values revealed an
equal amount of LucF and LucR RNA sequences, indicating the
absence of any cryptic promoter or splicing event that would
have increased the presence of one of the cistrons compared
with the other (24).
IRES elements have been discovered in several viral and cellular
RNA elements and are preferentially used to initiate translation of
speciﬁc mRNAs during cellular stress when overall global trans-
lation is compromised (25–27). Recent observations in tumor
models show a VEGF-D–driven lymphogenous spread by
Figure 1.
VEGF-D overexpression correlates with
the upregulation of eIF4GI and 4E-BP1.
A, immunohistochemical staining of
representative breast cancer tumors
(n ¼ 15) and normal breast epithelium
(n¼ 15) for VEGF-D, eIF4GI, and 4E-BP1.
Scale bar, 100 mm. B, quantitative RT-
PCR for breast, lung, and pancreatic
tumors (CA) compared with normal
tissue (NL;  , P < 0.001). C–E,
immunoblot analysis of VEGF-D and
4E-BP1 in mouse breast, lung, and
pancreatic tumors. D, quantiﬁcation by
densitometry of VEGF-D signal
normalized to GAPDH ( , P < 0.01).
E, quantiﬁcation by densitometry of
dephosphorylated 4E-BP1 normalized
to GAPDH ( , P < 0.001). n.s.,
nonsigniﬁcant.
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increasing lymph ﬂow through vessel dilation (28). Vessel dila-
tation is mainly observed during inﬂammation and is promoted
by an activation of the endothelial prostaglandin pathways (29).
Therefore, we submitted 4T1 transduced cell lines to physiologic
stresses associated with a local vasodilatation to identify which
stimulus is associated with IRES activation (Fig. 2C–I). VEGF-D
IRES activity was not affected by endoplasmic reticulum stress
(Fig. 2C), lipopolysaccharides (Fig. 2D), serum deprivation
(Fig. 2E), or hypoxia (Fig. 2F and G). In contrast, VEGF-D
IRES activity was signiﬁcantly activated in vitro after 20-minute
heat shock (Fig. 2H), whereas no activation was found for
EMCV control IRES (Fig. 2H) or hairpin (Fig. 2I).
VEGF-D synthesis promotes lymphatic vessel
dilatation and metastasis
The role of overexpressed VEGF-Dwas examined inmice breast
tumor models. We compared lymphatic-mediated metastasis in
4T1 tumors to orthotopic syngeneic 67NR low metastatic breast
tumors. Despite similar level of VEGF-DmRNA in 4T1 and 67NR
cell lines (Fig. 3A), we found that 67NR poorly expressed VEGF-D
comparedwith 4T1 (Fig. 3B andC). Surprisingly, this difference in
VEGF-D expression had no effect on tumor growth (Fig. 3D). To
investigate the role of VEGF-D in breast tumors lymphatic vessels,
we performed immunostaining using antibodies directed against
lymphatic vessel endothelial receptor (LYVE-1; ref. 30) and podo-
planin (Fig. 3E and Supplementary Fig. S3; ref. 31).
In these models, VEGF-D expression has no effect on tumor
lymphangiogenesis (Fig. 3E and F). In parallel, we found that the
tumor expressing a high level of VEGF-D (4T1) exhibited dilated
tumor lymphatic vessels compared to tumor with low level of
VEGF-D (67NR; Fig. 3G andH). As expected, the lymphatic vessel
dilatation is associated with an increase of tumor metastasis (Fig.
3I and J), but has no effect on draining lymph nodes lymphan-
giogenesis (Supplementary Fig. S4).
To identify in vivo VEGF-D IRES activity, bicistronic lentivec-
tor–transduced 4T1 and 67NR cell lines were injected in mice
mammary fat pad (Fig. 3K–N). IRES activity in tumors was
observed using immunodetection of ﬁreﬂy luciferase and quan-
tiﬁed by measuring luciferase activities after 7 and 14 days (Fig.
3K–N and Supplementary Fig. S4). We checked that the trans-
duction of the reporter genes did not affect tumor growth
(Supplementary Fig. S4). Interestingly, VEGF-D IRES activity
strongly increased in 4T1 tumors (Fig. 3K) compared with
EMCV IRES (Fig. 3L), but not in 67NR tumors (Fig. 3M), which
exhibit low VEGF-D protein levels. As expected, the EMCV viral
IRES, which is not involved in angiogenesis or lymphangiogen-
esis stimulation, was poorly (4T1) or not (67NR) activated
during tumorigenesis (Fig. 2L and N).
Figure 2.
VEGF-D mRNA contains an IRES element. A, schematics of the bicistronic expression cassettes subcloned into lentivectors. B, ratio of quantitative RT-PCR relative
values for LucR versus LucF, separated by VEGF-D 50UTR. C–G, in vitro VEGF-D IRES activity in 4T1 cell lines submitted to DTT-induced endoplasmic
reticulum stress (C), lipopolysaccharide (LPS) inﬂammatory stress (D), nutriment deprivation (-FCS) stress (E), and hypoxic stresses (F and G). H and I, in vitro
VEGF-D and EMCV IRES (H) activities in 4T1 cell lines submitted to heat shock stress (I). In vitro hairpin activity in 4T1 cell lines submitted to heat shock stress.
n.s., nonsigniﬁcant.
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Figure 3.
Tumor posttranscriptional induction of VEGF-D in vivo promotes lymphatic vessel dilatation.A, quantitative RT-PCR in 4T1 and 67NRmice breast cancer cell lines. B,
immunoblot analysis of VEGF-D in 4T1 and 67NR cell lines. C, quantiﬁcation of VEGF-D relative levels ( , P < 0.001). D, 4T1 and 67NR tumor growth analysis.
E and F, staining for Lyve-1 (green) and DAPI (blue) demonstrated VEGF-D–independent lymphangiogenesis during breast carcinoma development ( , P < 0.001).
Scale bar, 50 mm. G and H, staining for 1 (green) and DAPI (blue) demonstrated a signiﬁcant decrease of lymphatic vessel dilatation in tumor lacking VEGF-D
( , P < 0.001). Scale bar, 25 mm. I and J, staining for 1 (green), cytokeratin (red), and DAPI (blue) demonstrated a signiﬁcant decrease in lymph node metastasis
( , P < 0.001). Scale bar, 50 mm. K–N, in vivo VEGF-D IRES activity exhibits a signiﬁcant increase in 4T1 (K) compared with EMCV (L), whereas no activity was
promoted in 67NR for both IRESs (M and N). n.s., nonsigniﬁcant.
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These data demonstrate that the VEGF-D mRNA contains an
IRES that is activated during tumor growth in correlation with the
high levels of VEGF-D protein expression.
Altogether, our data suggest a cap-independent regulation of
VEGF-D translation that is not related with lymphangiogenesis,
but directly correlated with lymphatic vessels dilatation and
metastasis formation.
VEGF-D IRES exhibits twoalternative structures stabilizedbyan
ITAF: nucleolin
RNA structure plays important roles in every level of gene
regulation including translation initiation. Predicting how
mRNA 50UTRs fold into secondary structures is an essential
step in understanding the IRES activity. We then performed the
shape analysis method for probing of VEGF-D mRNA 50UTR
structure (Fig. 4A–C and Supplementary Fig. S5). The pattern of
benzoyl-cyanide modiﬁcations suggested that VEGF-D 50 UTR
is highly structured. Our structure prediction revealed the
presence of a pseudoknot (nucleotides 30–70) and several
stable helices. Nevertheless, enzymatic probing data (Fig. 4A
and Supplementary Fig. S5) showed a region (nucleotides 225–
229) with double reactivity toward both double strand (V1)
and single-strand probes (T2), and a native gel analysis con-
ﬁrmed the presence of two alternative structures (Fig. 4B). On
the basis of shape analysis, we identiﬁed a predictive folding of
VEGF-D IRES as shown in Fig. 4C.
The presence of alternative conformations at equilibrium has
been previously observed also for the VEGF-C IRES (5) and could
be an indication that the active structure might necessitate a
cofactor (18), that is, an ITAF or a speciﬁc eIF, to fold correctly.
IRES activation requires binding of canonical initiation factors
to initiate translation, but also other proteins called IRES trans-
acting factors (ITAF) that facilitate ribosome recruitment to the
IRES (32). ITAFs are RNA-binding proteins involved in other
aspects of RNA metabolism that are important in carcinogenesis
such as mRNA splicing, export and stability, and represent poten-
tial targeted therapy in certain types of cancer.
To identify VEGF-D ITAFs, we used an analytic method
coupling surface plasmon resonance and mass spectrometry
(BIA-MS; Fig. 4D–G), a technology recently validated for ITAF
identiﬁcation (33). Biotinylated VEGF-D and EMCV IRES RNAs
were immobilized on a BIACORE streptavidin sensorchip (Fig.
4D). Control (37C) or heat shock (42C) total cell protein
extracts were injected into the BIACORE T200 apparatus to
obtain the association phase (Fig. 4E and F). Bound proteins
were recovered and identiﬁed by nano-LC/MS-MS after tryptic
digestion. Interestingly, proteins bound the VEGF-D IRES with
a lower afﬁnity at 42C compared with 37C, whereas no
difference was observed for EMCV IRES (Fig. 4E and F). Mass
spectrometry analysis allowed identiﬁcation of a few proteins
bound to the VEGF-D IRES, including an RNA-binding protein,
nucleolin (Fig. 4E and F and Supplementary Fig. S5). As
nucleolin has previously been described to be an ITAF for viral
IRESs (20, 21), and plays a role in RNA stability of cellular
oncogenes such as Bcl2 (34), we investigated its effect on VEGF-
D IRES activity.
Nucleolin ITAF activity is mediated by its subcellular location
To study whether nucleolin participates in VEGF-D transla-
tional initiation during heat shock stress, we ﬁrst analyzed
protein expression in breast cancer cell lines (Fig. 5). Surpris-
ingly, no difference in nucleolin protein synthesis was observed
in cells submitted to an increased temperature (42C; Fig. 5A).
Interestingly, we found a delocalization of nucleolin from
the nucleus to the cell cytoplasm under heat shock (Fig. 5B
and C). The protein export is in accordance with previous
studies showing that ITAF activity depends on its subcellular
location (19).
To determine the role of nucleolin in VEGF-D IRES activity
under heat shock stress, we designed siRNAs against nucleolin
(Fig. 5D–J). Nucleolin protein synthesis is inhibited by siRNA,
but is not affected by control si scramble (Fig. 5D and E). To
decipher whether the nucleolin knock down could modulate
VEGFD synthesis, the VEGFD mRNA relative level and protein
expression were analyzed under heat shock condition after
knocking down the nucleolin. Despite a downregulation of
mRNA level, VEGF-D protein level is maintained, suggesting a
posttranscriptional regulation (Fig. 5F and G). In that context,
the knockdown of nucleolin induces a downregulation of
protein expression conﬁrming its role as an ITAF (Fig. 5G).
To investigate the effect of nucleolin on VEGF-D translation,
polysome proﬁling has been performed comparing VEGF-D
expression under stressed condition in polysomal fraction
from cells transfected with nucleolin siRNA (Supplementary
Fig. S6 and Fig. 5H). We observed a strong downregulation of
translated VEGFD in the absence of nucleolin at 42C com-
pared with 37C, suggesting that the downregulation of the
ITAF directly affects the association of the mRNA with the
polysomes (Fig. 5H). As expected, in the absence of nucleolin,
VEGF-D IRES activity was strongly decreased, whereas no effect
was observed for EMCV IRES activity (Fig. 5I). In this context,
VEGF-D IRES was affected by nucleolin knockdown, demon-
strating the role of nucleolin as an ITAF under heat stress
condition. To decipher whether transcription and cap-depen-
dent translation is regulated by heat shock stress, we performed
transcription and translation analysis on a gene involved in
vascular biology that does not contain an IRES: platelet growth
factor 4 (PF4). We show that PF4 is not regulated at the
transcriptional level under heat shock condition (Supplemen-
tary Fig. S6). As expected, we observed a downregulation of
PF4 mRNA under stressed condition in polysomal fraction
(Supplementary Fig. S6).
Figure 4.
VEGF-D 50UTR exhibits the presence of highly stable structures compatible with an IRES-driven mechanism of translation. A, quantiﬁcation and normalization
of the SHAPE analysis obtained by the QuSHAPE software. The 302 nucleotides long sequence of VEGF-D 50UTR has been split into three graphs
representing the 50 (graph I, top), graph II (middle), and 30 (graph III, bottom) regions. B, autoradiograms of RNA enzymatic probing experiments followed by
primer extension showing the localization of the enzymatic cleavages obtained with RNase V1 (V1), RNase T1 (T1), and RNase T2 (T2). (i) RNA, control RNA
without enzymes; (ii) V1, T1 and T2: three different increasing concentrations of the three RNAses; (iii) RNA sequencing ladders were run in parallel (U,C,G,A lanes on
each gel). C, putative secondary structure of the murine 50 UTR of VEGF-D mRNA. D, schematic representation of the BIACORE T200 analysis using surface
plasmon resonance. E and F, sensogram analysis for EMCV IRES (E) and VEGF-D IRES (F) coupled to mass spectrometry reveals the binding of a nuclear
protein: nucleolin.
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To conﬁrm the effect of nucleolin, we then used a pharmaco-
logic inhibitor, a synthetic ligand of nucleolin: N6L (23). As
expected, we observed a decrease of VEGF-D IRES activity in the
presence of nucleolin inhibitor (Fig. 5J).
COX-2 inhibitors abolish VEGF-D stress response by
modulating nucleolin expression
Recent studies have demonstrated that VEGF-D regulates
the tumor-draining collecting lymphatic vessels dilatation
through a prostaglandin (PG)-dependent mechanism, consis-
tent with the elevated levels of inﬂammatory mediators, such
as PGs (28, 35). VEGF-D modulates COX-2–derived PGE2 to
promote tumor progression and metastasis leading to a che-
moprotective effect of COX-2 inhibitors (NSAIDs) by reduc-
ing PGE2 levels. To determine the role of COX-2 inhibitors on
molecular regulations of VEGF-D expression, we evaluated the
effect of sc236 in vitro (Fig. 6A–E). As shown in Fig. 5, the
increased temperature has no effect on nucleolin synthesis
(Fig. 6A). Surprisingly, we observed a COX-2 inhibitor down-
regulation of nucleolin synthesis at both 37C and 42C (Fig.
6A), suggesting that the drug interferes with VEGF-D trans-
lational initiation by modulating its ITAF synthesis. Using
immunocytodetection, we found that cytoplasmic nucleolin
was hardly detected upon sc236 treatment in 4T1 cell lines
under heat shock conditions (Fig. 6B and C). In parallel,
COX-2 inhibitor abolished heat shock–induced VEGF-D IRES
activity in 4T1 cells (Fig. 6D), but had no effect on 67NR
cell lines (Fig. 6E). To investigate whether COX-2 inhibitor
could modulate VEGF-D translation initiation in vivo, tumor-
bearing mice were treated every 2 days during 10 days by
intraperitoneal injection of COX-2 inhibitor (Fig. 6F–J). As
expected, we found a downregulation of nucleolin expression
in tumors (Fig. 6F). IRES activities were studied in vivo at
day 7 (1–2 mm diameter, well vascularized, nonmetastatic)
and day 14 (4–8 mm diameter, necrotic, metastatic) to
compare low-stressed to high-stressed condition (Fig. 6G).
As expected, the EMCV viral IRES is not affected by the COX-2
inhibition. The VEGF-D IRES is activated at day 14, and this
effect is abolished by COX-2 inhibitor (Fig. 6G), whereas no
difference was observed in tumor growth (Supplementary
Figure 5.
VEGF-D IRES activity is regulated by
nucleolin. A, immunoblot of nucleolin in
mouse cell lines. B, staining for nucleolin
(green) and DAPI (blue) in 4T1 submitted
to heat shock; scale bar, 5 mm (left); scale
bar, 25 mm (right). C, quantiﬁcation of the
percentage of 4T1 cell lines, which
exhibits a cytoplasm staining of nucleolin
under increased temperature
(, P < 0.001). D, immunoblot of nucleolin
in lysates of 4T1 cells incubated in
physiologic (37C) or heated (42C)
temperature and treated with or without
siRNA against nucleolin (Si) or a
scrambled (Sc) siRNA control.
E, densitometric quantiﬁcation of the
immunoblot (#, P < 0.05). F, quantitative
VEGF-D RT-PCR on total mRNA from 4T1
cells incubated in physiologic (37C) or
heated (42C) temperature. G,
immunoblot of VEGF-D in lysates of 4T1
cells incubated in physiologic(37C) or
heated (42C) temperature and treated
with or without siRNA against nucleolin
(Si) or a scrambled (Sc) siRNA control.
H, comparison of VEGF-D mRNA relative
levels in polysomal mRNA from 4T1 cells
incubated in physiologic (37C) or heated
(42C) temperature and treated with or
without siRNA against nucleolin (Si) or a
scrambled (Sc) siRNA control ( , P <
0.01). I, VEGF-D IRES activity in 4T1 cells
incubated in physiologic (37C) or heated
(42C) temperature and treated with or
without siRNA against nucleolin (Si)
or a scrambled (Sc) siRNA control
(#, P < 0.05). J, VEGF-D IRES activity in
4T1 cells incubated in physiologic (37C)
or heated (42C) temperature and
treated with adjuvant (mannitol) or
nucleolin inhibitor (N6L; #, P < 0.05).
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Fig. S7). In parallel, we observed a strong decrease of lym-
phatic vessel diameter in tumors (Fig. 6H and I) associated
with a vasoconstriction of the tumor-draining collecting
vessels in COX-2 inhibitor–treated mice (Fig. 6J). These
data demonstrated for the ﬁrst time that an anti-inﬂamma-
tory drug can modulate growth factor synthesis under stress
condition by controlling an ITAF subcellular location and
synthesis.
Discussion
Tumor metastases are a leading cause of cancer-related mor-
tality and can be promoted by both intrinsic and extrinsic
factors in tumor cells. This study has identiﬁed an original
translational regulation mechanism of VEGF-D expression
under stress conditions in primary tumors promoting lymphat-
ic vessel increased diameter that can be reversed by NSAIDs
acting on ITAF expression. Translational initiation is promoted
by eIF4E initiation factor binding to the mRNA. Under stress
condition, eIF4E is targeted by the translational inhibitor 4E-
Binding Protein 1 (4E-BP1) in its hypophosphorylated form,
which leads to inhibition of cap-dependent, but not cap-inde-
pendent, translation (36). Also, translation reprograming was
previously reported in inﬂammatory breast cancer due to an
overexpression of eIF4GI and overexpression/dephosphoryla-
tion of 4E-BP1 (37, 38).
Figure 6.
VEGF-D IRES activity is modulated by
COX-2 inhibitor. A, quantiﬁcation of
nucleolin-positive pixels in 4T1 cells
submitted to heat shock ( , P < 0.01).
B, staining for nucleolin (green) and
(blue) in heated 4T1 cell lines incubated
with COX-2 inhibitor (sc236). C,
quantiﬁcation of the percentage of 4T1
cell lines incubated with sc236, which
exhibit a cytoplasmstaining of nucleolin
under increased temperature
( , P < 0.001). D, stimulation of VEGF-D
and EMCV IRES activity in 4T1 cell line
(#, P < 0.05). E, stimulation of VEGF-D
and EMCV IRES activity in 67NR cell line
(#, P < 0.05). F, immunoblot of
nucleolin in 4T1-bearing mice treated
with mouse sc236. G, stimulation of 4T1
VEGF-D IRES activity in vivo is inhibited
by sc236. H, staining for LYVE-1 (green)
and (blue) demonstrated a signiﬁcant
decrease of lymphatic vessel dilatation
in sc236-treated 4T1 tumors. I,
quantiﬁcation of lymphatic vessel
diameters in vivo in sc236-treated
4T1 tumors ( , P < 0.01). J, Evans blue
perfusion of the 4T1 draining lymphatics
exhibits a vessel dilatation that is
abolished after sc236 treatment. n.s.,
nonsigniﬁcant.
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We found a colocalization of these two markers with VEGF-
D in human breast carcinoma, suggesting a cap-independent
translation initiation of VEGF-D mRNA. Moreover, we show
that VEGF-D transcript levels are reduced in mice tumors,
whereas VEGF-D protein levels are increased due to a switch
from cap-dependent to IRES-dependent VEGF-D translation.
Notably, this regulation seems to depend on an increased
temperature, but is not regulated by hypoxia as it has been
previously described for other (lymph)angiogenic growth fac-
tors, such as VEGF-A and VEGF-C, two related and homolo-
gous members of the VEGF family (5). This feature distin-
guishes VEGF-D from the other hypoxia-induced (lymph)
angiogenic growth factors. Importantly, we found two alter-
native structures for VEGF-D 50UTR, suggesting an equilibrium
between basal and stressed conditions to facilitate the ITAF
binding. Switching from cap-dependent to IRES-dependent
translation of VEGF-D in tumor cells required adapter protein
called ITAFs. The VEGF-D IRES might be regulated by distinct
ITAFs, which would be activated during heat shock (and in
inﬂammation), but not during hypoxia. Our ﬁndings reveal
that nucleolin, a nucleolar protein involved in the control of
transcription of ribosomal RNA, is translocated to the cyto-
plasm in response to heat shock and controls VEGF-D mRNA
translation after binding to the IRES region. Nucleolin has
been previously described as an ITAF for virus IRESs such as
poliovirus (20). Recently, it has been found to enhance
cellular IRES-dependent translation of speciﬁcity protein-1
(Sp1), a transcription factor involved in tumor cells prolifer-
ation (22, 39). These results are in accordance with ﬁndings
showing that IRES-dependent translation initiation is regulat-
ed by ITAF's subcellular location (19).
Tumor cells spread to distant organs via lymphatic using
two mechanisms: lymphangiogenesis and lymphatic dilata-
tion. Here, we demonstrated that breast tumors lacking
VEGF-D expression do not exhibit a defect in primary tumor
or lymph nodes lymphangiogenesis, but have a reduced
amount of dilated lymphatic vessels associated with an inhi-
bition of metastasis. Our ﬁndings suggested that this process is
restricted to breast cancer, in agreement with previous studies
showing a correlation between metastases and dilated lym-
phatic vessels in breast cancer patients (40).
We know for decades that inﬂammation is a major inducer
of prostaglandin-induced vasodilatation (29). Previous studies
reported that expression of VEGF-D by cancer cells promoted
tumor lymphatic vessels dilatation and metastasis by regulating
prostaglandins produced by the collecting lymphatic endothe-
lium (1). COX-2 inhibitors, the most common NSAIDs, reduce
VEGF-D–driven metastasis by reversing the morphologic
changes in collecting lymphatic vessels. In this study, we
demonstrated that COX-2 inhibitor–induced lymphatic vessel
constriction is in part due to a downregulation of VEGF-D IRES
translation initiation. We observed that the VEGF-D IRES
activity is abolished by NSAIDs during tumor development.
Notably, vessel diameters were reduced in COX-2 inhibitor–
treated mice. These data indicate that lymphatic vessels plas-
ticity is controlled by a regulatory loop involving VEGF-D
protein synthesis and prostaglandin signaling (Supplementary
Fig. S8).
Our study may be relevant to provide the ﬁrst evidence of a
translational initiation control of the lymphatic vessels dila-
tation, a major pathophysiologic event in tumor metastasis.
A key ﬁnding of our study is that increased temperature
mediates lymphangiogenic growth factor responses, through
the suppression of cap-dependent and an increase of IRES-
mediated mRNA translation. Collectively, our data allow us to
propose the existence of two VEGF-D translational control
pathways involved in cancer dissemination that depends on
stresses associated with inﬂammation. A nucleolar protein, the
nucleolin, which can provide a novel therapeutic target for
lymphatic vessel plasticity during tumor inﬂammation, con-
trols this mechanism.
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